Table 1.
Study Design | Setting | Target | HRQoL Measurement | Summary of Result | Reference |
---|---|---|---|---|---|
Cross sectional | Johannesburg, South Africa, February 2015-January 2018 | DR-TB Patients; ≥ 18 years old (n= 149) | Short Form-36 (SF-36) | Patients with ADR experience were more likely to have lower MCS (aRR 2.24 95% CI 1.53–3.27) and PCS (aRR 1.52 95% CI 1.07–2.18). | Sineke et al, 201922 |
Cross sectional | Namibia, January-April 2015 | MDR-TB patients in the final month or had completed the treatment within the past 3 months; aged 17–54 years (n= 36) | Short Form-8 (SF-8) | There was no significant different between patients reporting zero to two ADR (median HRQoL score = 56.8; 44.4–56.8) with those reporting three or more ADR (median HRQoL score = 55.2 (38.6–56.8); (p value = 0.34)). | Sagwa et al, 201630 |
Cross sectional | Belo Horizonte, Brazil. March-December 2015. | Both DR-TB and DS-TB patients, >18 years old (n= 73) | Abbreviated World Health Organization Quality of Life Questionnaire (WHOQOL-Bref) | There were significant association between the type of ADR and HRQoL in univariate analysis (p value =0.016) and in multivariate analysis (p value =0.012). | Valadares et al, 202020 |
Abbreviations: HRQoL, health-related quality of life; ADR, adverse drug reaction; MCS, mental component summary; PCS, physical component summary; aRR, adjusted relative risk; CI, confidence interval; DR-TB, drug resistant tuberculosis; MDR-TB, multi-drug resistant tuberculosis.